Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT-008 Combination in Metastatic Pancreatic Adenocarcinoma
NCT03127124Phase 2Withdrawn
- Sponsor
- NantPharma
- Start
- Feb 2018
- Primary completion
- Dec 2023
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel polymeric micelle in pancreatic adenocarcinoma (PDAC), sponsored by NantPharma. Planned start Feb 2018; status: withdrawn.
02
Drugs
paclitaxel polymeric micelle
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03127124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127124.